General contact

Head Office
Novartis International AG
CH-4002 Basel

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.

Clinical Trials

  • Connecting to clinical trial information

    Open partnerships within the oncology care community enable us to conduct high-quality clinical trials with competitive timelines and aid in the discovery of new uses of our medicines to benefit patients. Novartis is currently conducting clinical trials in a number of disease areas.

  • The WIDE program

    The WIDE (Worldwide Initiative to Develop Everolimus) Program is a global initiative that encompasses a broad range of malignancies. Through this program, Novartis Oncology is conducting clinical studies of everolimus as a single agent and in combination with other anticancer treatments.

    This website provides a concise overview of Phase II and Phase III clinical trials with everolimus (RAD001). All of these oncology trials are being conducted within the WIDE Program—and are either enrolling or will soon be enrolling participants. We hope that you will keep these clinical trials in mind when treating oncology patients who may be appropriate candidates for participation in a clinical trial.

    The WIDE Program Website

  • PRI3M Trials

    PRI3M (Pioneering Research of PI3K inhibitors in Malignancies) is a program of clinical research sponsored by Novartis.

    Here you will find information about the PI3K/Akt/mTOR pathway and the clinical trials with the Novartis PI3K inhibitor buparlisib (BKM120), which are currently enrolling patients with metastatic Breast cancer and metastatic NSCLC (Non Small Cell Lung Cancer).

    PRI3M Website

  • The GOLD trials

    The GOLD (Global Oncologic Learnings for Dovitinib) Trials are a series of global initiatives led by Novartis that encompass a broad range of malignancies, such as renal cell carcinoma (RCC), breast cancer, gastric cancer, hepatocellular carcinoma (HCC), multiple myeloma, and urothelial cancer. Through this program, Novartis is conducting clinical studies of dovitinib (TKI258) as a single agent and in combination with other agents.1

    1. Data on file. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.

    The GOLD Trials

  • is a website service provided by the United States National Institutes of Health (NIH). The NIH, through its National Library of Medicine, has developed this website in collaboration with the Food and Drug Administration (FDA), as a result of the FDA Modernization Act, which was passed into law in November 1997.

    Go to Novartis clinical trials posted on

  • IFPMA clinical trials portal